# Adaptive Chemotherapy for Pd-l1 High REsEctablE NSCLC: A Chemo-PHREE Trial

> **NCT07746388** · PHASE2 · NOT_YET_RECRUITING · sponsor: **University of Maryland, Baltimore** · enrollment: 30 (estimated)

## Conditions studied

- Nsclc
- NSCLC Stage II
- NSCLC, Stage III
- NSCLC Stage IIIB
- Resectable Lung Non-Small Cell Carcinoma

## Interventions

- **DRUG:** Cemiplimab

## Key facts

- **NCT ID:** NCT07746388
- **Lead sponsor:** University of Maryland, Baltimore
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09-01
- **Primary completion:** 2030-09-01
- **Final completion:** 2031-09-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-08-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07746388

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07746388, "Adaptive Chemotherapy for Pd-l1 High REsEctablE NSCLC: A Chemo-PHREE Trial". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07746388. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*